Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity

Area of Science:

• Hepatology
• Toxicology
• Biomarker Discovery

Background:

• Acetaminophen (APAP) hepatotoxicity is a significant clinical challenge.
• Current diagnostic tools are insufficient for assessing toxicity in various exposure scenarios (chronic, sequential, modified-release, delayed presentation).
• There is a critical need for specific and robust biomarkers for APAP toxicity.

Purpose of the Study:

• To review promising biomarkers for acetaminophen toxicity.
• To evaluate their properties regarding exposure type, specificity, and clinical utility.
• To highlight the role of new technologies in APAP hepatotoxicity biomarker research.

Main Methods:

• Literature review of existing and emerging biomarkers.
• Analysis of biomarker properties and clinical applicability.
• Discussion of advanced technologies like extracellular vesicles and omics techniques.

Main Results:

• Several promising biomarkers are under evaluation, including APAP derivatives, mitochondrial damage markers, apoptosis/necrosis markers, and circulating microRNAs.
• New technologies, particularly extracellular vesicle isolation combined with omics, offer novel avenues for biomarker research.
• These advanced methods have potential applications in predicting and monitoring APAP-induced liver injury.

Conclusions:

• The development of reliable biomarkers is essential for managing acetaminophen toxicity.
• Emerging technologies hold significant promise for advancing the field of hepatotoxicity biomarker discovery.
• Further research is needed to fully realize the potential of these new technologies in clinical practice.